IL-17 induces the production of inflammatory mediators (mainly neutrophils) and stimulates the expansion and tissue infiltration of myeloid cells, thereby promoting cancer progression, and it has also been associated with the tumor microenvironment, immunotherapy, and resistance of tumor cells to radiation therapy and chemotherapy (85). This evidence concerns the gene IL17A and neoplasm.